Cargando…

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Patients with advanced melanoma treated with immune checkpoint inhibitors can experience ongoing disease control after treatment discontinuation without subsequent systemic anticancer therapy. We previously defined a novel outcome, treatment-free survival (TFS), as the time between protocol therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mantia, Charlene M., Werner, Lillian, Stwalley, Brian, Ritchings, Corey, Tarhini, Ahmad A., Atkins, Michael B., McDermott, David F., Regan, Meredith M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles: Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691370/ https://www.ncbi.nlm.nih.gov/pubmed/34855329 http://dx.doi.org/10.1097/CMR.0000000000000793

Ejemplares similares

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
por: Regan, Meredith M, et al.
Publicado: (2021)

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
por: Regan, Meredith M., et al.
Publicado: (2019)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
por: Regan, Meredith M., et al.
Publicado: (2021)

Evaluating sensitivity to classification uncertainty in latent subgroup effect analyses
por: Loh, Wen Wei, et al.
Publicado: (2022)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Inconsistency between overall and subgroup analyses
por: Wang, Hongyue, et al.
Publicado: (2022)

A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma
por: Wang, Liuying, et al.
Publicado: (2023)

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
por: Dubin, Krista, et al.
Publicado: (2016)

Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape
por: Srivastava, Neeharika, et al.
Publicado: (2014)

Re-Identification of Patient Subgroups in Uveal Melanoma
por: Nguyen, Thi Hai Yen, et al.
Publicado: (2021)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review
por: Chow, Dominic, et al.
Publicado: (2016)

Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses
por: Coghill, David R., et al.
Publicado: (2020)

Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition
por: Gelato, K A, et al.
Publicado: (2018)

PD-1 as a potential target in cancer therapy
por: McDermott, David F, et al.
Publicado: (2013)

Are there sensitive subgroups for the effects of airborne particles?
por: Zanobetti, A, et al.
Publicado: (2000)

A framework to assess the added value of subgroup analyses when the overall treatment effect (TE) was significant
por: Sun, Hong, et al.
Publicado: (2013)

Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
por: Anagnostou, Valsamo, et al.
Publicado: (2020)

The lack of statistical power of subgroup analyses in meta-analyses: a cautionary note
por: Cuijpers, Pim, et al.
Publicado: (2021)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Challenges and Solutions to Pre- and Post-Randomization Subgroup Analyses
por: Desai, Manisha, et al.
Publicado: (2014)

Absolute vs. relative effects—implications for subgroup analyses
por: Andersen, Lars W.
Publicado: (2021)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma
por: Ammann, Nadine L., et al.
Publicado: (2022)

Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma
por: Tabari, Azadeh, et al.
Publicado: (2023)

How to perform prespecified subgroup analyses when using propensity score methods in the case of imbalanced subgroups
por: Chatelet, Florian, et al.
Publicado: (2023)

DNA methylation subgroups in melanoma are associated with proliferative and immunological processes
por: Lauss, Martin, et al.
Publicado: (2015)

Distinct genomic features across cytolytic subgroups in skin melanoma
por: Roufas, Constantinos, et al.
Publicado: (2021)

Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
por: Waaler, Jo, et al.
Publicado: (2020)

Sampling and sensitivity analyses tools (SaSAT) for computational modelling
por: Hoare, Alexander, et al.
Publicado: (2008)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

The use of immunotherapy in the treatment of melanoma
por: Achkar, Tala, et al.
Publicado: (2017)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma
por: Ravi, Praful, et al.
Publicado: (2022)

Empirically derived phenotypic subgroups – qualitative and quantitative trait analyses
por: Wilcox, Marsha A, et al.
Publicado: (2003)

Three simple rules to ensure reasonably credible subgroup analyses
por: Burke, James F, et al.
Publicado: (2015)

Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison
por: Wang, Chen, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ntca250i68234a41i5bqpbpg8r